Login to Your Account

Onyx Next Big M&A Pick?

Nexavar Success Piques Bids in HCC; Late-Stagers Line Up

By Randy Osborne

Monday, March 8, 2010
After years of plodding work, mostly by pharma firms, several are pushing products to the finish line for liver cancer, also known as hepatocellular carcinoma, but handicapping their chances is tricky. "They're all going to struggle to unseat Nexavar [in first-line therapy]" from Onyx Pharmaceuticals Inc., said Marcus Hoyle, oncology analyst for Decision Resources.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription